Page 1 of Clinical Trials for Drug Alemtuzumab Campath Registered Trademark, 7 Total Matches
- 1RecruitingLast Updated: March 20, 2012Condition(s): Peripheral Blood Stem Cell Transplantation; Anemia, Sickle Cell; Graft-Versus-Host Disease; Sirolimus (Rapamune(Registered Trademark)); Alemtuzumab (Campath(Registered Trademark))
- 2RecruitingLast Updated: April 7, 2012Condition(s): Lymphoproliferative Disorders
- 3RecruitingLast Updated: April 6, 2012Condition(s): Relapsed or Refractory Severe Aplastic Anemia; Severe Aplastic Anemia
- 4RecruitingLast Updated: March 20, 2012Condition(s): Congenital Hemolytic Anemia; Diamond-Blackfan Anemia
- 5Active, not recruitingLast Updated: March 21, 2012Condition(s): Severe Aplastic Anemia
- 6Active, not recruitingLast Updated: April 13, 2012Condition(s): Aplastic Anemia
- 7CompletedLast Updated: June 16, 2010Condition(s): Myositis, Inclusion Body
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?term=Drug+Alemtuzumab+Campath+Registered+Trademark
